SHANGHAI, June 27,
2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd.
(Abbisko Therapeutics) announced that it has presented new phase II
clinical data of its highly selective FGFR4 inhibitor
irpagratinib (ABSK011) in combination with atezolizumab for the
treatment of advanced hepatocellular carcinoma(HCC)at the 2024
ESMO-GI Congress. The presentation highlights that 220mg BID
of irpagratinib in combination with atezolizumab demonstrated
promising antitumor activity with an objective response rate (ORR)
of 50% in FGF19+ HCC patients.
ESMO-GI, a world-renowned gastrointestinal oncology conference,
is being held in Munich, Germany,
from June 26 to 29, 2024.
Abbisko presentations at ESMO-GI 2024:
Title: A Phase 2 Study of Irpagratinib (ABSK-011) plus
Atezolizumab in Patients with Advanced Hepatocellular Carcinoma
(HCC)
Poster display number:171P
Poster display session: Hepatocellular and non-biliary
liver cancer
Poster display date and time: 27 June
2024, 15:35-16:30 PM (UTC+1)
Summary:
At the 2024 ESMO-GI conference, Abbisko Therapeutics debuted new
clinical trial results with the combination of irpagratinib and
atezolizumab. In HCC patients with FGF19 overexpression, the
objective response rate (ORR) was 50% (5/10)in the 220 mg BID
cohort, demonstrating this novel combination therapy has notable
benefits in enhancing the ORR. Notably, strong efficacy and good
safety were also observed in patients who had previously received
immune checkpoint inhibitor (ICI) therapy, providing further
evidence that targeting FGF19-FGFR4 may provide a much-needed
differentiated treatment option for HCC.
Given the encouraging preliminary results from this study,
Abbisko plans to explore dual/triple combinations with irpagratinib
in earlier lines of therapy for HCC. Abbisko continues to look
forward to combination approaches with irpagratinib to better
address HCC and bring hope to patients, with aims to conduct
further research and innovation in this area.
Background:
Hepatocellular carcinoma (HCC) is the most common type of
primary liver cancer and ranks as the sixth most prevalent cancer
and third leading cause of death worldwide. Dysregulation of
FGF19-FGFR4 signaling accounts for approximately 30% of HCC and
plays a pivotal role in driving HCC tumorigenesis. Irpagratinib is
a highly potent and selective FGFR4 inhibitor, with potential to
become a first-in-class or best-in-class FGFR4 inhibitor. Abbisko
Therapeutics previously presented clinical data from its
first-in-human study of irpagratinib at the 2023 ESMO Annual
Meeting, demonstrating promising anti-tumor activity as a single
agent with an ORR of 40.7% in FGF19 overexpressed late-line HCC
patients.
To further explore the therapeutic potential of irpagratinib,
Abbisko is conducting a phase 2 clinical trial of irpagratinib in
combination with atezolizumab. This trial is investigating
irpagratinib in combination with atezolizumab, a PD-L1 antibody, in
FGF19+ advanced HCC patients, to understand safety and
efficacy.
About Abbisko
Founded in April 2016, Abbisko
Therapeutics Co., Ltd., (Stock Code on the Hong Kong Stock
Exchange: 2256.HK), is an oncology-focused
biopharmaceutical company founded in Shanghai, dedicated to the discovery and
development of innovative medicines that treat unmet medical needs
in China and globally. The Company
was established by a group of seasoned drug hunters with rich
R&D and managerial expertise from top multinational
pharmaceutical companies. Since its founding, Abbisko has built an
extensive pipeline of 16 innovative small molecule programs focused
on precision oncology and immuno-oncology.
For more information, please visit www.abbisko.com.
View original
content:https://www.prnewswire.com/news-releases/50-orr-impressive-clinical-trial-data-for-irpagratinib-combined-with-atezolizumab-in-advanced-hepatocellular-carcinoma-stuns-esmo-gi-congress-302184300.html
SOURCE Abbisko